Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roadmap for HEOR

By HEOR Staff Writer

April 21, 2026

In this update, we analyze the evolution of the FDA Accelerated Approval Pathway since the 2022 Food and Drug Omnibus Reform Act (FDORA), highlighting measurable improvements, ongoing evidentiary gaps, and policy recommendations critical for health economics and outcomes research (HEOR), pricing,...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence Gaps and Patient Ac...

By João L. Carapinha

April 20, 2026

Healthcare stakeholders were informed in the Netherlands that Chronic Pain Rehabilitation through Interdisciplinary Medical Specialist Rehabilitation (IMSR) will be removed from the Dutch basic health insurance package for most patients. Under the new ruling by Zorginstituut Nederland, chronic pa...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
An Executive Order signed by President Donald J. Trump on April 18, 2026, will significantly advance psychedelic therapy access for serious mental illness. By removing regulatory and scheduling barriers, the order directs the FDA to issue Commissioner’s National Priority Vouchers for eligible psy...